AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 58(3), 1998, pp. 358-364
Copyright © 1998 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thuma, P.
Right arrow Articles by Gordeuk, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thuma, P.
Right arrow Articles by Gordeuk, V.
Related Collections
Right arrow Malaria
Right arrow Plasmodium
American Journal of Tropical Medicine and Hygiene, Vol 58, Issue 3, 358-364
Copyright © 1998 by American Society of Tropical Medicine and Hygiene

Research Articles


Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans

PE Thuma, NF Olivieri, GF Mabeza, G Biemba, D Parry, S Zulu, FF Fassos, RA McClelland, G Koren, GM Brittenham, and VR Gordeuk

While the parenteral iron-chelating agent desferrioxamine B has anti-malarial activity in humans, the usefulness of an orally active chelator for this indication has not been investigated previously in vivo. We conducted a prospective, double-blind, placebo-controlled, cross-over trial of deferiprone (L1; CP20; 1,2-dimethyl-3-hydroxypyridin-4-one) in 25 adult Zambians with asymptomatic Plasmodium falciparum parasitemia. Deferiprone was administered daily for three or four days in divided doses of 75 or 100 mg/kg of body weight, dosages that are effective for treating iron overload. No reduction in asexual intra-erythrocytic parasites was observed during or after deferiprone treatment. The mean peak plasma concentration of deferiprone (108.9 +/- 24.9 micromol/L) achieved was within the range demonstrated to inhibit the growth of P. falciparum in vitro, but the systemic exposure as determined by the 24-hr plasma concentration-time curve would not be predicted inhibit growth in vivo. No evidence of deferiprone-associated hematological toxicity was noted in this short-term study of these subjects, all of whom had clinical evidence of normal body iron stores. Because of the risk of neutropenia and other adverse effects with higher doses or prolonged use of the chelator, additional trials of deferiprone as a sole anti-malarial agent would not seem to be justified. In contrast, further efforts are needed to develop other orally active iron-chelating agents specifically for their anti-malarial action.


This article has been cited by other articles:


Home page
Mult SclerHome page
K.M. Mitchell, A.L. Dotson, K.M. Cool, A. Chakrabarty, S.H. Benedict, and S.M. LeVine
Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis
Multiple Sclerosis, November 1, 2007; 13(9): 1118 - 1126.
[Abstract] [PDF]


Home page
JAMAHome page
K. S. Griffith, L. S. Lewis, S. Mali, and M. E. Parise
Treatment of Malaria in the United States: A Systematic Review
JAMA, May 23, 2007; 297(20): 2264 - 2277.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Tropical Medicine and Hygiene.